For people with severe, refractory autoimmune disease, existing treatments often fall short, leaving patients at risk of progressive tissue and organ damage, disability, and a diminished quality of life.

Most potentially transformative therapies in development for autoimmunity centre on therapies originally designed for oncology. While potentially efficacious, these therapies may also cause substantial toxicity. Autoimmunity patients desperately need transformational AND safe therapies.

Quell is developing potentially transformative therapies designed specifically for the needs in complex autoimmunity to safely restore immune balance.

Autoimmune disease is driven by many immune cell types working together, not a single culprit.

Broad control. Quell's engineered nTregs are designed to restore broad control across multiple cell types involved in complex autoimmune inflammation, including autoreactive T and B cells and inflammatory cytokines, and to steer macrophages and fibroblasts towards tissue repair.

Built-in stability. Our Phenotype-Lock™ technology is designed to keep nTregs stable, even under inflammatory stress, without producing pro-inflammatory cytokines to avoid the toxicities linked to cell-depleting therapies, such as cytokine release syndrome (CRS) or local immune effector cell-associated toxicity syndrome (LICATS).